Valuation: InspireMD

Market Cap 32.05M 28.26M 26.73M 24.23M 45.48M 3.08B 45.88M 320M 123M 1.57B 120M 118M 5.04B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.05M 28.26M 26.73M 24.23M 45.48M 3.08B 45.88M 320M 123M 1.57B 120M 118M 5.04B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 1.59x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 31/12/2019
Director of Finance/CFO 58 24/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 01/06/2017
Director/Board Member 68 06/02/2013
Director/Board Member 62 31/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 32.05M
+1.26%+1.67%-24.46%+1.96% 106B
-0.10%-2.18%-23.52%-0.39% 11.29B
-0.01%-1.84%+98.39%+108.07% 9.35B
+0.33%-2.04%-49.55%-67.02% 4.11B
-1.79%+2.37%-23.53%+24.68% 2.49B
+4.54%-3.35%-5.26%-63.48% 2.02B
-0.20%-2.80% - - 1.9B
-0.58%-2.60%-23.08%-32.61% 1.52B
Average -0.04%+0.47%-7.29%-4.11% 17.29B
Weighted average by Cap. +0.99%+1.71%-16.40%+6.02%

Financials

2026 *2027 *
Net sales 9.8M 8.64M 8.17M 7.41M 13.9M 940M 14.03M 97.74M 37.7M 480M 36.79M 35.99M 1.54B 20.13M 17.75M 16.79M 15.22M 28.57M 1.93B 28.82M 201M 77.45M 986M 75.59M 73.94M 3.17B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-